Andrew A. Young
AndrewA.Young,ChiefScientificOfficerofIntarciaTherapeutics,Inc.,ResearchTrianglePark,NC,U.S.A.AndrewYoungreceivedhisM.B.,Ch.B.(M.D.)andhisPh.D.inPhysiologyfromtheUniversityofAuckland,NewZealand.FollowingclinicalpracticewiththeAucklandHospitalBoard,andasageneralmedicalpractitioner,hejoinedthefacultyasalecturerintheDepartmentofPhysiologyattheUniversityofAuckland.In1984hebecameaClinicalResearchScientistattheNationalInstitutesofHealthinPhoenix,Arizona,wherehestudiedinsulinresistanceanddiabetes.Fromthere,hemovedtoBadNauheim,Germany,whereasaMax-PlanckFellowhestudiedtheelectrophysiologyofpainandtemperaturesensation.In1989AndrewYoungjoinedAmylinPharmaceuticalsIncinSanDiegoasthefoundingphysiologist,becomingVicePresident,Researchin1998andasVicePresidentandSeniorResearchFellowin2002.Heleadphysiologiccharacterizationofthehormone,amylin,ananalogofwhich,pramlintide,waslaunchedasSYMLIN,afirst-in-classtreatmentforinsulin-requiringdiabetes.Hewasalsoresponsiblefortheacquisitionandpreclinicaldevelopmento